Cargando…

Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients

OBJECTIVES: To compare the total number of adverse events (AEs) before and after mesenchymal stromal cell (MSC) infusion in refractory JIA and to evaluate its effectiveness. METHODS: Single-centre Proof of Mechanism Phase Ib, open label intervention study in JIA patients previously failing all biolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swart, Joost F, de Roock, Sytze, Nievelstein, Rutger A J, Slaper-Cortenbach, Ineke C M, Boelens, Jaap J, Wulffraat, Nico M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758577/ https://www.ncbi.nlm.nih.gov/pubmed/31070229 http://dx.doi.org/10.1093/rheumatology/kez157

Ejemplares similares

What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
por: Swart, Joost F, et al.
Publicado: (2013)

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis
por: Swart, Joost F, et al.
Publicado: (2018)

Monitoring patients with juvenile idiopathic arthritis using health-related quality of life
por: Doeleman, Martijn J. H., et al.
Publicado: (2021)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2023)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

Mesenchymal stromal cells suppress synovial fluid-derived t cells from juvenile idiopathic arthritis patients in vitro
por: Wienke, J, et al.
Publicado: (2014)

ISBT 128 coding and labeling for cellular therapy products
por: Slaper-Cortenbach, Ineke
Publicado: (2010)

Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis
por: Kip, Michelle M A, et al.
Publicado: (2022)

Costs of Hospital‐Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System
por: Kip, Michelle M. A., et al.
Publicado: (2022)

PReS-FINAL-2107: In vitro investigation into mesenchymal stromal cells as a potential therapeutic in juvenile arthritis
por: Wienke, J, et al.
Publicado: (2013)

Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals?
por: Schoemaker, Casper G., et al.
Publicado: (2020)

The human microbiome and juvenile idiopathic arthritis
por: Verwoerd, Anouk, et al.
Publicado: (2016)

Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry
por: van Straalen, Joeri W., et al.
Publicado: (2023)

Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study
por: van Straalen, Joeri W., et al.
Publicado: (2022)

A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2020)

Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2021)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study
por: ter Haar, Nienke M., et al.
Publicado: (2019)

Feasibility of quantitative sensory testing in juvenile idiopathic arthritis
por: Mensink, Maarten O., et al.
Publicado: (2022)

Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review
por: Vonk, Lucienne A., et al.
Publicado: (2015)

Establishing consensus on ethics, traceability and biovigilance for medical products of human origin
por: Ashford, Paul, et al.
Publicado: (2021)

Early predictors of prognosis in juvenile idiopathic arthritis patients: a systematic literature review
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

Immunomodulatory actions of methotrexate on T cells in juvenile idiopathic arthritis
por: Ćalasan, Maja Bulatović, et al.
Publicado: (2012)

Methotrexate restores effector T cell responsiveness in juvenile idiopathic arthritis
por: Bulatović, Maja, et al.
Publicado: (2011)

Intranasal Administration of Human MSC for Ischemic Brain Injury in the Mouse: In Vitro and In Vivo Neuroregenerative Functions
por: Donega, Vanessa, et al.
Publicado: (2014)

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review
por: van Dijkhuizen, EH Pieter, et al.
Publicado: (2014)

Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review
por: Kip, Michelle M. A., et al.
Publicado: (2019)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis
por: Grazziotin, Luiza R., et al.
Publicado: (2022)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, EH Pieter, et al.
Publicado: (2011)

Identifying disrupted biological factors and patient-tailored interventions for chronic fatigue in adolescents and young adults with Q-Fever Fatigue Syndrome, Chronic Fatigue Syndrome and Juvenile Idiopathic Arthritis (QFS-study): study protocol for a randomized controlled trial with single-subject experimental case series design
por: Vroegindeweij, Anouk, et al.
Publicado: (2022)

Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis
por: Nelson, Meghan Corrigan, et al.
Publicado: (2023)

Challenging the silent temporomandibular joint paradigm in children with juvenile idiopathic arthritis
por: de Sonnaville, Willemijn F. C., et al.
Publicado: (2022)

Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study
por: Grazziotin, Luiza R., et al.
Publicado: (2022)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, Pieter E H, et al.
Publicado: (2011)

A three minute- screening tool for temporomandibular joint involvement in children with juvenile idiopathic arthritis
por: Giancane, Gabriella, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gq9d55q828dsvh16urbrn8dj72